期刊文献+

垂体生长激素腺瘤合并阻塞性睡眠呼吸暂停低通气综合征及睡眠低氧的危险因素 被引量:7

Risk factors of obstructive sleep apnea hypopnea syndrome and sleep hypopnea in patients with growth hormone-secreting pituitary adenoma
下载PDF
导出
摘要 目的探讨垂体生长激素(GH)腺瘤合并阻塞性睡眠呼吸暂停低通气综合征(OSAHS)及睡眠低氧(SH)的危险因素。方法严格按照入组及排除标准选取85例垂体GH腺瘤患者,所有患者入院后均行睡眠呼吸监测。收集患者的临床资料、化验结果、影像资料进行对比分析,并采用二元logistic回归分析相关危险因素。结果该组垂体生长激素腺瘤患者合并OSAHS的发生率为62.4%(53/85),合并SH的发生率为75.3%(64/85)。进行回归分析得出年龄(OR=1.107)及BMI(OR=1.166)为OSAHS的危险因素,BMI(OR=1.334)为SH的危险因素。结论高龄及BMI增加是垂体GH腺瘤患者合并OSAHS及SH的独立危险因素。术前常规行睡眠呼吸监测,早期识别患者并指导患者保持健康体重,是降低患者呼吸系统相关死亡率的有效方法。 Objective To investigate the risk factors contributing to the development of obstructive sleep apnea hypopnea syndrome(OSAHS) and sleep hypopnea(SH) in patients with growth hormone-secreting pituitary adenoma(GHPA).Methods A total of 85 patients with GHPA recruited strictly according to the inclusion and exclusion criteria underwent sleep monitoring overnight. Clinical manifestations, laboratory data and magnet resonance images were collected for analysis of the risk factors of GHPA and SH using binary logistic regression analysis. Results The prevalence rate of OSAHS was 62.4%(53/85), and that of SH was 75.3%(64/85) in the recruited patients with GHPA. Regression analysis showed that age(OR=1.107)and BMI(OR=1.166) were the risk factors for OSAHS, and BMI(OR=1.334) was the risk factor of SH. Conclusions Ageing and an increased BMI are independent risk factors for OSAHS and SH in patients with GHPA. Preoperative sleep monitoring should be routinely conducted to ensure early diagnosis of OSAHS and SH, and patients with GHPA should be advised to control their body weight to lower the mortality associated with the respiratory system.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2015年第10期1501-1504,1518,共5页 Journal of Southern Medical University
关键词 垂体生长激素腺瘤 肢端肥大症 阻塞性睡眠呼吸暂停低通气综合征 睡眠低氧 growth hormone-secreting pituitary adenoma acromegaly obstructive sleep apnea hypopnea syndrome OSAHS sleep hypopnea
  • 相关文献

参考文献20

  • 1Melmed S. Acromegaly[J]. N Engl J Med, 1990, 322(14): 966-77. 被引量:1
  • 2Hern~adez-Gordillo D, Ortega-G6mez Mdel R, Galicia-Polo L, et al. Sleep apnea in patients with acromegaly. Frequency, characterization and positive pressure titration[J]. Open Respir Med J, 2012, 6: 28-33. 被引量:1
  • 3Fatti LM, Scacchi M, Pincelli AI, et al. Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly[J]. Pituitary, 2001, 4 (4): 259-62. 被引量:1
  • 4Weiss V, Sonka K, Pretl M, et al. Prevalence of the sleep apnea syndrome in acromegaly population[J]. J Endocrinol Invest, 2000, 23(8): 515-9. 被引量:1
  • 5Sonka K, Weiss V, Dost~lov~i S, et al. Sleep apnea syndrome in acromegaly. Treatment and development-- retrospective analysis[J]. Sb Lek, 1999, 100(1): 45-52. 被引量:1
  • 6Vannucci L, Luciani P, Gagliardi E, et al. Assessment of sleep apnea syndrome in treated acromegalic patients and correlation of its severity with clinical and laboratory parameters [J]. J Endocrinol Invest, 2013, 36(4): 237-42. 被引量:1
  • 7Chevallier M, Pontier S, Sedkaoui K, et al. Characteristics of sleep apnea syndrome in a cohort of patients with acromegaly [J].Rev Mal Respir, 2012, 29(5): 673-9. 被引量:1
  • 8Dunn LK, Nemergut EC. Anesthesia for transsphenoidal pituitary surgery[J]. Curt Opin Anaesthesiol, 2013, 26(5): 549-54. 被引量:1
  • 9中国肢端肥大症诊治指南(2013版)[J].中华医学杂志,2013,93(27):2106-2111. 被引量:44
  • 10阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版)[J].柳州医学,2012,25(3):162-165. 被引量:88

二级参考文献19

  • 1Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly- 2011 update. Endocr Pract, 2011, 17 Suppl 4:1-44. 被引量:1
  • 2Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab, 2000, 85:526-529. 被引量:1
  • 3Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab, 2002, 87: 4054-4058. 被引量:1
  • 4Brabant G, von zur Mtihlen A, Wtister C, et al (German KIMS Board). Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a muhicenter study. Horm Res, 2003, 60:53-60. 被引量:1
  • 5Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest, 2003, 26 : 1242-1247. 被引量:1
  • 6Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure". Eur J Endocrinol,2005, 152 : 379-387. 被引量:1
  • 7Merza Z. Modem treatment of acromegaly. Postgrad Med J, 2003, 79 : 189-194. 被引量:1
  • 8Arosio M, Ronchi CL, Epaminonda P, et al. New therapeutic options for acromegaly. Minerva Endocrino, 2004, 29:225- 239. 被引量:1
  • 9Tabaee A, Anand VK, Barr6n Y, et al. Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg, 2009, 111:545-554. 被引量:1
  • 10Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab, 2008, 93 : 2984 -2990. 被引量:1

共引文献133

同被引文献54

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部